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ARTICLE OPEN
Needle-free delivery of measles virus vaccine to the lower
respiratory tract of non-human primates elicits optimal
immunity and protection
Rik L. de Swart 1, Rory D. de Vries1, Linda J. Rennick 2, Geert van Amerongen1,4, Stephen McQuaid3, R. Joyce Verburgh1,5,
Selma Yüksel1, Alwin de Jong1, Ken Lemon3,6, D. Tien Nguyen1, Martin Ludlow2,7, Albert D. M. E. Osterhaus1,7 and W. Paul Duprex 2
Needle-free measles virus vaccination by aerosol inhalation has many potential beneﬁts. The current standard route of vaccination
is subcutaneous injection, whereas measles virus is an airborne pathogen. However, the target cells that support replication of live-
attenuated measles virus vaccines in the respiratory tract are largely unknown. The aims of this study were to assess the in vivo
tropism of live-attenuated measles virus and determine whether respiratory measles virus vaccination should target the upper or
lower respiratory tract. Four groups of twelve cynomolgus macaques were immunized with 104 TCID50 of recombinant measles
virus vaccine strain Edmonston-Zagreb expressing enhanced green ﬂuorescent protein. The vaccine virus was grown in MRC-5 cells
and formulated with identical stabilizers and excipients as used in the commercial MVEZ vaccine produced by the Serum Institute of
India. Animals were immunized by hypodermic injection, intra-tracheal inoculation, intra-nasal instillation, or aerosol inhalation. In
each group six animals were euthanized at early time points post-vaccination, whereas the other six were followed for 14 months to
assess immunogenicity and protection from challenge infection with wild-type measles virus. At early time-points, enhanced green
ﬂuorescent protein-positive measles virus-infected cells were detected locally in the muscle, nasal tissues, lungs, and draining
lymph nodes. Systemic vaccine virus replication and viremia were virtually absent. Infected macrophages, dendritic cells and tissue-
resident lymphocytes predominated. Exclusive delivery of vaccine virus to the lower respiratory tract resulted in highest
immunogenicity and protection. This study sheds light on the tropism of a live-attenuated measles virus vaccine and identiﬁes the
alveolar spaces as the optimal site for respiratory delivery of measles virus vaccine.
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INTRODUCTION
Measles remains a leading cause of childhood morbidity and
mortality. Live-attenuated measles virus (MV) vaccines are safe
and effective, and high coverage in two-dose regimens has
successfully interrupted endemic transmission in large geographic
areas.1 However, measles still caused an estimated 134,200 deaths
in 2015,2 and vaccine refusal based on religious and/or
philosophical objections has led to measles resurgence in Europe
and the Americas.3, 4
Wild-type MV is one of the most contagious human pathogens,
is spread by airborne transmission and causes an acute systemic
disease.5 Measles is associated with transient but severe immune
suppression, which results in increased susceptibility to opportu-
nistic infections.6, 7 Live-attenuated MV vaccines were introduced
in the early 1960s at a time when worldwide millions of children
were dying of measles every year. Introduction of MV vaccination
has consistently reduced childhood mortality in every geographic
region.8 Despite their success, live-attenuated MV vaccines also
have limitations, including dependency on maintaining the cold-
chain, requirement for trained health-care workers and the need
for sterile hypodermic needles and concomitant safe waste
disposal. Needle-free MV vaccination regimens were developed
to address some of these issues and administration of the vaccine
by aerosol inhalation (AI) has been considered as a promising
technology.9 Initially, clinical trials using aerosolized measles
vaccine were performed in Mexico and these demonstrated the
feasibility of this vaccination route.10 Recent studies conﬁrmed
that aerosol measles vaccination was equivalent or superior to
injection as booster vaccine.11 However, when used for primary
immunization of infants, aerosol vaccination resulted in lower
seroconversion levels than standard injection.12 A randomized,
controlled trial of aerosol vaccination in infants 9–12 months of
age conﬁrmed that aerosol vaccination was immunogenic, but
aerosol delivery induced lower seroconversion rates than sub-
cutaneous (SC) injection (85% and 95%, respectively).13
Regulatory authorities consider a vaccine and its administration
route as a single entity. Consequently, both preclinical and clinical
studies were required to achieve licensure for MV aerosol
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vaccination. To support licensing we previously compared
administration of the MV Edmonston-Zagreb (MVEZ) vaccine strain
via AI, dry powder inhalation and injection in non-human
primates.14 Aerosol vaccination induced similar levels of neutraliz-
ing antibodies and T-cell responses as detected in the injection
group, and protection from challenge infection with a wild-type
MV was comparable. Dry powder aerosol vaccination was less
effective than injection in this study.15 However, in a more recent
study successful immunization of macaques by an aerosolized dry
powder MV vaccine was reported,16 and this approach was shown
to be safe in a phase I clinical trial in humans.17
Despite the fact that live-attenuated MV vaccines have been used
for almost 50 years, there is still a fundamental lack of under-
standing of the in vivo tropism of the virus and the molecular basis
of attenuation remains elusive. This hampers rational development
of next-generation delivery strategies that could be transformative
in the developing world by mitigating challenges associated with
virus thermostability. Live-attenuated MV must replicate in the host
to induce protective immune responses, and alternative routes of
administration may well deliver the vaccine to different target cells
than those infected following injection. In recent years, we have
used recombinant (r) MV strains expressing ﬂuorescent proteins to
study wild-type MV tropism in vitro and in vivo.18–22 These viruses
express a ﬂuorescent reporter protein from an additional transcrip-
tion unit (ATU), which has the advantage that the entire cytoplasm
of an infected cell is ﬂooded with the reporter proteins facilitating
sensitive detection of infected cells by ﬂow cytometry, immuno-
ﬂuorescence and/or immunohistochemistry.23 We recently
described an rMV based on the MVEZ vaccine strain expressing
enhanced green ﬂuorescent protein (EGFP), which was produced
using a miniaturized (laboratory-scale) industrial process using cells
and protocols provided by the Serum Institute of India. This reporter
virus permitted detection of small numbers of MV-infected cells in
the muscle of vaccinated non-human primates in the ﬁrst week
following injection.24 In addition, we optimized methodology for
dose estimation and aerosol delivery in non-human primates.25
Based on these foundational studies we now report results of a
large-scale vaccination study in cynomolgus macaques comparing
four different routes of immunization. The aim of the study was
to compare vaccine virus replication, tropism, immunogenicity and
protection, and determine whether MV vaccination via the
respiratory route should target the upper or lower respiratory tract
(LRT).
RESULTS
Study design
Four groups of 12 cynomolgus macaques were immunized by
intra-muscular (IM) injection, intra-tracheal (IT) inoculation, intra-
nasal (IN) instillation, or AI of rMVEZEGFP(3).24 Six animals from
each group were euthanized at early time points in the virus
replication and tropism arm of the study, the other six were
followed-up for 14 months post-vaccination (MPV) to assess
immunogenicity and protection from wild-type MV challenge
infection (Fig. 1a). For logistical reasons the study was performed
in two parallel sessions (1 and 2) comprising half of the animals
from each of the groups (Fig. 1b and Supplementary Table 1). To
comply with Dutch laws on the use of genetically modiﬁed
Fig. 1 Study design. a Schematic representation of the experimental groups included in the vaccination study. All animals received the same
dose of the same vaccine, administered via four different routes. Colors used for the four treatment groups correspond to symbol colors
(Figs. 2, 3, 4, and 5). A detailed list of animals and samples is provided in Table S1. b For logistical reasons, the experiment was performed in
two parallel sessions (1 and 2), as illustrated. Each session included six animals of each group, of which three were euthanized at 3, 5, or 7 DPV
for assessment of replication and tropism (subgroups a), and three were followed up for assessment of immunogenicity and protection
(subgroups b). The time points of vaccination (V) and challenge (C) are indicated by V1/V2 and C1/C2, respectively. DPV days post-vaccination,
MPV months post-vaccination. Two groups of two seronegative animals were included as challenge controls at C1 and C2
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organisms, vaccinations were performed in high efﬁciency
particulate air (HEPA)-ﬁltered negatively pressurized animal
biosafety level (ABSL)-3 isolators.
Replication
Clinical specimens collected during the ﬁrst 9 days post-
vaccination (DPV) were screened for the presence of MV-
infected (EGFP-positive) cells by combining ﬂow cytometry
(ﬂuorescence-activated cell sorting (FACS)), ultraviolet (UV) micro-
scopy and virus isolation to assess vaccine virus replication. FACS
analysis of unstained broncho-alveolar lavage (BAL) cells was a
sensitive method for detection of EGFP-positive cells in the LRT, as
illustrated by a negative and positive sample at ﬁve DPV (Fig. 2a).
The highest frequencies of EGFP-positive BAL cells were consis-
tently detected in animals of groups 3 (IT) and 4 (AI), while
infected cells were undetectable in the BAL of most animals in
groups 1 (IM) or 2 (IN) (Fig. 2b). This was compatible with virus
isolation data obtained from BAL cells: in 24 out of 48 animals
EGFP-positive BAL cells were detected by FACS analysis, and we
were able to isolate MV from BAL cells from 23 out of these 24
animals, predominantly at 3, 5, or 6 DPV (results not shown).
FACS scatter plots of BAL samples showed that at least two
separate populations of cells were present in BAL, one with low
forward scatter (FSC) and side scatter (SSC), compatible with
lymphocyte scatter in FACS analysis of peripheral blood mono-
nuclear cell (PBMC) and lymph node samples, and the second with
higher FSC and SSC values (Fig. 2c, left panel). A number of BAL
samples containing EGFP-positive cells were stained with cell-
speciﬁc antibodies to assess the phenotype of the MV-infected
cells. The lymphoid fraction contained B-cells (CD20+), T-cells
(CD3+) as well as CD3−CD20− cells, but the majority of the EGFP-
positive BAL cells in the lymphoid fraction were T-lymphocytes
(Fig. 2c). The BAL cell population with high FSC/SSC mostly
contained MV-infected myeloid CD11c+HLA-DR+ cells, most likely
alveolar macrophages or dendritic cells (Fig. 2c).
A similar FACS analysis to that used for BAL cells was performed
using unstained PBMC, collected at different DPV from animals in
both arms of the study. With the exception of two samples
collected from animals in group 1 (IM), frequencies of EGFP-
positive events in PBMC were consistently below 10 per million
events (Fig. 2d). These observations are consistent with virus
isolation data: all attempts to isolate vaccine virus from PBMC at
multiple DPV were unsuccessful.
Muscle slices, prepared from animals euthanized 3, 5, or 7 DPV,
were screened by UV microscopy to detect replicating rMVEZEGFP
at the site of administration. As reported previously, we detected
EGFP-positive cells interdigitating the musculature at the injection
site of all six animals in group 1 (IM), and in none of the animals
vaccinated via the respiratory routes (Fig. 2e).24 Lung slices were
prepared from animals euthanized 3, 5, or 7 DPV to assess MV
infection of the LRT. These were screened for EGFP-positive cells
by UV microscopy and high frequencies of MV-infected cells were
detected in 6/6 and 5/6 animals of groups 3 (IT) and 4 (AI),
respectively (Fig. 2e). In group 2 (IN), the lungs of one animal
contained several foci of MV-infected cells (compatible with
detection of EGFP-positive BAL cells in the same animal, see
Fig. 2b), while in the lungs of two other animals in this group only
a single EGFP-positive cell was detected. Infected cells were not
detected in the lungs of other animals in groups 1 and 2. Nasal
tissues (nasal septum, nasal concha, and nasal epithelium) were
analyzed systematically by UV microscopy to detect MV-infected
cells in the upper respiratory tract (URT, see explanation of sample
collection in Fig. S1). In addition, virus isolation was performed
from throat and nasal swabs. MV-infected cells were only detected
in the nose and throat of animals immunized via respiratory routes
(groups 2–4), although not in all animals of these groups (Fig. 2e).
Absolute numbers of EGFP-positive cells detected in the URT of
animals immunized by IN instillation or AI were substantially lower
than those detected in the LRT of animals immunized via the IT or
AI routes. In conclusion, MV vaccination by injection or delivery to
the LRT resulted in detection of EGFP-positive cells in samples
consistent with the route of delivery.
Tropism
Targeted pathological assessment of a wide range of formalin-
ﬁxed samples collected during necropsy was used for further
assessment of viral tropism. This approach was straightforward at
the peak of wild-type MV infection, but proved more challenging
upon MV vaccination due to the limited numbers of EGFP-positive
cells. UV microscopy-positive samples were dissected, formalin-
ﬁxed and parafﬁn-embedded (FFPE) and multiple 7 µm sections
were prepared from leveled tissues to permit small numbers of
EGFP-positive cells to be identiﬁed.
Since formalin ﬁxation destroys EGFP autoﬂuorescence, serial
sections were prepared and one in every ten was stained with an
anti-EGFP monoclonal antibody and HRP-conjugated secondary
antibody and counterstained with hematoxylin (Fig. 3a). In most
FFPE slices we were unable to detect MV-infected cells, but in a
few samples MV-infected cells were identiﬁed in the lung sections.
Serial sections of these slices were used for dual immunoﬂuor-
escent labeling. MV-infected cells were mainly cytokeratin-
negative (Fig. 3b, c), and some MV-infected cells expressed
CD68 demonstrating a macrophage lineage (Fig. 3d, e). Equivalent
MV-infected cells were present in nasal epithelia in animals from
group 2 (IN; data not shown). In conclusion, MV vaccine virus
predominantly replicated in myeloid and lymphoid cells and rarely
in epithelial cells.
Immunogenicity
Animals were followed for MV-speciﬁc immune responses for 14
MPV. Serum antibody responses were detected by enzyme linked
immunosorbent assay (ELISA, Fig. 4a, b, d), virus neutralization
(Fig. 4c) or indirect immunoﬂuorescence for MV fusion (MV-F) or
hemagglutinin (MV-H) glycoprotein-speciﬁc antibodies (Fig. 4e, f).
Animals vaccinated by IT inoculation (blue symbols) consistently
showed highest antibody levels, whereas samples from AI
administered (green symbols) and IM (grey symbols) injected
animals showed slightly lower responses. In all assays, lowest serum
antibody levels were consistently observed in animals immunized by
IN instillation (red symbols). Serological proﬁles were comparable to
cellular immune responses measured at 35, 45, or 411 DPV: in vitro
PBMC stimulation assays consistently resulted in highest levels of
interferon-gamma (IFN-γ) production in supernatants of cells
collected from animals in groups 3 (IT) and 4 (AI), and lowest
responses in animals of group 2 (IN, Fig. 4g–i). In conclusion, vaccine
delivery to the LRT resulted in higher immunogenicity than
vaccination by IM injection, but exclusive delivery to the URT
consistently resulted in lower immune responses.
Protection
Fourteen MPV, all twenty-four animals in the immunogenicity arm
of the study, and four additional seronegative control animals,
were challenged with wild-type MV strain Bilthoven by IT
inoculation with a dose of 104 TCID50 (based on titration in
Vero-hCD150 cells)26 as described previously.27 At the moment of
challenge infection (438 DPV = 0 days post-challenge; DPC), MV-
speciﬁc serum antibody levels in the majority of vaccinated
animals were above previously identiﬁed immunological corre-
lates of protection of 120−200mIU/ml28 (Fig. 5a, b).
Frequencies of MV-infected BAL cells and PBMC were measured
using an infectious center assay to assess the level of protection to
challenge infection (Fig. 5c, d). As expected the highest virus loads
were detected in challenge control animals, although high levels
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were also detected in animals immunized by IN instillation (group 2),
and two out of six animals immunized by IM injection (which also
had the lowest serum antibody levels at time point C0) also
showed substantial virus loads in BAL cells collected 3 or 6 DPC.
Only two out of six IN immunized animals had detectable virus
loads in PBMC. Measurement of MV-speciﬁc serum antibody
responses at different time points post-challenge (Fig. 5e, f)
demonstrated accelerated secondary immune responses in all
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vaccinated animals as compared to slower primary responses in
the challenge control animals (black symbols). Animals in group 4
(AI) showed the most rapid onset of a secondary immune
response, with four out of six animals showing strong increases in
speciﬁc antibody levels between 3 and 6 DPC (Fig. S2). In
conclusion, all vaccinated animals were largely protected from
systemic wild-type MV replication, but also showed secondary
immune responses demonstrating the absence of sterilizing
immunity after MV vaccination.
One animal (I–31; group 3, session 1, IT) failed to recover from
anesthesia after collection of clinical specimens 9 DPC. A full
necropsy was performed to establish a possible cause of death.
Replicating MV was not detected and no gross pulmonary lesions
were observed. Histopathological evaluation showed a very mild
neutrophilic tracheitis and bronchitis that may have been
associated with the MV-speciﬁc immune response. No lesions in
any tissues were found that could explain the cause of death. This
led to the conclusion that the unexpected death resulted from
anesthesia.
In conclusion, immunogenicity and protection, as determined
by inhibition of wild-type MV replication, were closely related.
Lowest relative protection levels (as shown by challenge virus
replication) were detected in animals immunized by IN instillation
and in two out of six animals immunized by IM injection. Delivery
of MV vaccine to the LRT (groups 3 and 4) resulted in high
immunogenicity and this was associated with high levels of
protection from wild-type MV replication.
DISCUSSION
Live-attenuated virus vaccines have had a profound impact on
human and animal health. Development of measles vaccines
started 50 years ago, based on the ﬁrst MV isolate that was
adapted to grow on embryonated chicken eggs and embryo
ﬁbroblasts.29 Measles vaccines are safe and effective and have
successfully interrupted endemic MV transmission in large parts of
the world.30 However, neither the molecular basis of attenuation
nor the in vivo tropism of live-attenuated measles vaccine viruses
are completely understood.
We have previously used rMVs generated using wild-type MV
sequences obtained directly from clinical specimens, and there-
fore unmodiﬁed by tissue culture adaptation, for in vitro and
in vivo pathogenesis studies. An ATU encoding a ﬂuorescent
reporter protein had a negligible effect on virulence and allowed
sensitive detection of infected cells. Studies employing these rMVs
have improved our understanding of wild-type MV entry,21, 31
dissemination19, 20 and transmission.32 Furthermore, these viruses
were essential in elucidating how wild-type MV causes immune
suppression.7 The possibility of identifying single MV-infected cells
as early as 2 days post-infection in tissues and organs21 suggested
that it is possible to perform tropism studies following vaccination.
This approach was piloted following immunization of macaques
by IM injection and permitted the identiﬁcation of the primary
target cells in the muscle.24 Here we extended this approach, and
identiﬁed the tropism of measles vaccine viruses after IN
instillation, IT inoculation or AI. To facilitate these studies we
optimized aerosol administration and dose estimation of MV
vaccine to non-human primates.25
Repeated tissue culture passage of wild-type MV, which
normally uses CD150 or nectin-4 as cellular entry receptors,33, 34
resulted in attenuated MV vaccine strains that may use the
ubiquitously expressed protein CD46 as an entry receptor.35, 36
Even though CD46 is used by live-attenuated MV in vitro, careful
pathological assessments show scant evidence that this is the case
in vivo.20, 24, 37 Here, we show that rMVEZ was predominantly
detected in CD3+ T-lymphocytes, major histocompatibility com-
plex (MHC) class II+CD11c+ dendritic cells and CD68+ macro-
phages after delivery of live-attenuated virus to the respiratory
tract. These cell types all express CD150 showing infection by
vaccine viruses is mediated by the primary entry receptor for wild-
type MV. Evidence for in vivo usage of CD46, i.e., infection of
CD150-/nectin-4- cells, was not obtained during these studies even
though there are enormous numbers of CD46-positive cells in
close proximity to MV-infected centers. Collectively, these data
demonstrate the importance of using relevant animal models of
vaccination to determine the in vivo tropism of live attenuated
vaccine viruses, rather than relying on extrapolations from in vitro
data.
Since wild-type MV is transmitted via the respiratory route, it
has been suggested that immunization via the airways might
improve vaccine immunogenicity and efﬁcacy compared to
injection.38 Initial clinical trials using aerosolized measles vaccine
were performed in Mexico and these demonstrated the feasibility
of this route of delivery.10 Subsequent pre-clinical and clinical
studies conﬁrmed vaccination efﬁcacy and demonstrated no
evidence for serious adverse events.9 Moreover, aerosol measles
vaccination might result in improved mucosal immune
responses,39 similar to other respiratory pathogen vaccines.40–42
The potential of delivering measles vaccine as an aerosol,
alongside the desire to reduce and/or eliminate needle use in the
developing world, led us to perform a unique study in non-human
primates comparing the immunogenicity of rMVEZ delivered via
different routes of respiratory administration. The particle size of
the aerosol (mass median aerodynamic diameter 3.5 µm) was
chosen to allow deposition of a substantial fraction of the inhaled
dose into the LRT.25 Robust humoral immune responses were
induced by IM injection, IT inoculation and AI, whereas IN
instillation induced poor antibody responses. Furthermore, direct
delivery of live-attenuated vaccine to the LRT via IT inoculation or
AI gave superior humoral and cellular responses compared to IM
injection. These results demonstrate that the immunogenicity of
MVEZ after primary immunization with equivalent dosage was
comparable when the vaccine was delivered by AI or injection.14
Fig. 2 Replication. Detection of EGFP-positive cells in clinical specimens collected from non-human primates immunized with rMVEZEGFP(3)
via four different routes of administration. a Detection of EGFP-positive cells in BAL cells by ﬂow cytometry: examples of a negative (left) and
positive (right) sample. Please note that the narrow diagonal band represents non-speciﬁc autoﬂuorescent cells, the EGFP-positive events are
contained in the triangular gate in the upper left of the PE—EGFP plots. b Based on these FACS analyses, frequencies of EGFP-positive BAL cells
are shown for animals in the four treatment groups (including animals of both subgroups a and b). c FACS staining of a representative EGFP-
positive BAL cell sample. Two cell populations were distinguishable in scatter plots: cells with large FSC and SSC values (myeloid gate)
predominantly contained CD11c+ and HLA-DR+ myeloid cells while cells with low FSC and SSC values (lymphoid gate) contained CD20+
B-lymphocytes and CD3+ T-lymphocytes but in majority (approximately 80%) were not phenotyped. Reverse gating of the EGFP-positive
myeloid and lymphoid cells showed that these predominantly were CD11c+HLA-DR+ myeloid and CD3+ lymphoid cells, respectively. d
Extremely low to undetectable levels of EGFP-positive cells in PBMC indicated absence of viremia after vaccination. e Detection of EGFP-
positive cells in muscle (by UV microscopy, as reported previously),24 lung (ﬂuorescence microscopic screening of lung slices as described
previously),58 TB-LN (> 10 EGFP-positive cells per 106 TB-LN, similar to panels b and d), throat (virus isolation), or nose (combination of virus
isolation and UV microscopy screening of tissues collected (Fig. S1). Each block represents one positive animal. BAL broncho-alveolar lavage,
PBMC peripheral blood mononuclear cells, TB-LN tracheo-bronchial lymph node
Needle-free measles vaccination of macaques
RL de Swart et al.
5
Published in partnership with the Sealy Center for Vaccine Development npj Vaccines (2017)  22 
Fig. 3 Tropism. Macaques were euthanized by exsanguination 3, 5, or 7 DPV. During necropsy, lungs were inﬂated with low-melting point
agarose and allowed to solidify on ice. Lung slices were screened by UV microscopy for the presence of EGFP-positive cells. Seven micrometer
sections were prepared from leveled, ﬁxed, and parafﬁn embedded tissues to permit small numbers of EGFP-positive cells to be identiﬁed.
a Hematoxylin counterstained anti-EGFP immunohistochemical staining of a lung slice, showing evidence of EGFP-positive cells in brown
(see inset, positive cells indicated by arrows); b, c EGFP (green)/4’,6-diamidino-2-phenylindole (DAPI; blue) / cytokeratin (red) staining (single
ﬂuorescence scans shown in insets); d, e: EGFP (green)/DAPI (blue)/CD68 (red) staining (single ﬂuorescence scans shown in insets). Arrow in panel
e indicates CD68 and EGFP co-localization. Images shown were collected from animal T-41 (see Table S1, group 4 A (AI), euthanized 5 DPV).
Av alveoli, Br bronchiole
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All animals vaccinated via the IT and AI route still had MV-
speciﬁc, neutralizing antibodies at the moment of challenge
infection at 14 MPV. Interestingly, these antibodies had waned in
6/6 IN vaccinated animals and 2/6 IM vaccinated animals. This was
reﬂected post-challenge and infectious virus was more likely to be
recovered from BAL cells obtained from animals without
detectable antibodies (6/6 IN, 2/6 IM, 0/6 IT, 0/6 AI and 4/4
challenge controls). A signiﬁcant boosting of antibodies, char-
acteristic of a secondary immune response, was observed in all
vaccinated animals and this was both faster and stronger than the
primary immune responses observed in the challenge control
animals. Rapid increases in MV-speciﬁc antibodies was most
evident in animals vaccinated via AI. Although this study was not
designed to assess vaccine safety, it is important to note that no
indications for adverse events associated with these non-
conventional vaccination routes were noted.
Even though aerosol delivery of live-attenuated MV vaccine
offers promise,38, 43, 44 clinical studies in children have produced
variable results. Although effective in inducing secondary immune
responses as booster vaccination,45 primary vaccination of infants
proved inferior to vaccination by standard injection,13, 46, 47
contradictory to the results we obtained in non-human primates.
Extending exposure time of infants to aerosol resulted in
improved responses,48 suggesting delivery of insufﬁcient vaccine
as a potential explanation for the reduced effectiveness in infants
with low tidal breathing volumes and irregular breathing patterns.
These issues, and the fact that in our study immunogenicity of IT
inoculation was superior to AI, highlight the need to determine
the parameters for normalization of the dose delivered to the LRT
during aerosol delivery, if the goal of aerosol MV vaccination is
ever to be realized.
Dry powder inhalation has also been examined as an alternative
to nebulized AI.16, 17, 49, 50 This approach avoids the need for
vaccine reconstitution and allows packaging of individual doses in
a thermostable formulation, which may reduce dependence on
cold chain maintenance. Microneedle patches containing measles
vaccine are considered as another alternative, and have similar
advantages.51 Patches contain a stabilized formulation of vaccine
that dissolves in the skin minutes after application, thereby
avoiding the use of hypodermic needles. Microneedle delivery
patches were immunogenic in macaques,52 and studies with a
combination of microneedle patches and an rMV vaccine strain
encoding a ﬂuorescent reporter protein could support further
development and elucidate the tropism of live-attenuated MV
vaccine in the dermis and/or epidermis of the skin.
Since live-attenuated virus vaccines typically contain a low
antigenic dose, replication in the host is essential for induction of
protective immune responses. Primary vaccine virus replication in
professional antigen presenting cells (expressing MHC class II) in
the LRT, as we show here, could facilitate the induction of robust
Fig. 4 Immunogenicity. Virus-speciﬁc immune responses after immunization of non-human primates with rMVEZEGFP(3) via four different
routes of administration. Panels a–f show MV-speciﬁc serum antibody responses measured by six different assays: a Serion IgG ELISA, with
results expressed in milli-international units per ml (mIU/ml); b in house MV IgG ELISA, with results expressed in optical density at 450 nm
(OD450); c focus reduction neutralization test (FRNT), with results expressed in international units per ml (IU/ml); d MV nucleoprotein (MV-N)-
speciﬁc IgG ELISA, with results expressed in OD450; e MV fusion (MV-F) glycoprotein-speciﬁc FACS-measured IgG immunoﬂuorescence
(expressed in arbitrary ﬂuorescence units, AFU); f MV hemagglutinin (MV-H) glycoprotein-speciﬁc FACS-measured IgG immunoﬂuorescence
(expressed in AFU). Results are shown as means± standard error of six animals per group. Panels g–i show MV-speciﬁc cellular responses
measured using PBMC collected 35 (g), 45 (h), or 411 (i) DPV. Brieﬂy, PBMC were stimulated with UV-inactivated MV (UV-MV), mock antigen
(UV-Vero) or medium. Culture supernatants were harvested after 2 days for measurement of the concentration of IFN-γ by ELISA. Bars
represent the means, while symbols represent responses of individual animals. Results of statistical analysis (Two-way analysis of variance with
Tukey’s multiple comparison test) are indicated by the following symbols if P-values were below 0.05: $ (IM vs. IT),! (IM vs. AI), and (IM vs. IN),
# (IT vs. AI), % (IT vs. IN), * (AI vs. IN)
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immune responses. This demonstrates that it is critical to
understand replication and tropism of existing live-attenuated
vaccines, as this will inform the optimal route of delivery of
vaccines. In conclusion, we show that delivery of live-attenuated
MV vaccines to the LRT is a biologically feasible method of
measles vaccination. These studies support the notion that inferior
immunogenicity following primary immunization of infants can be
attributed to suboptimal vaccine virus delivery to the LRT in the
short exposure time used in this trial.13 It remains to be seen
whether the collective will exists to re-evaluate respiratory MV
vaccination in clinical studies in infants.
METHODS
Ethics statement
Animal experiments were conducted in compliance with European
guidelines (EU directive on animal testing 86/609/EEC) and Dutch
legislation (Experiments on Animals Act, 1997). The study protocol was
approved by Stichting Dier Experimenten Commissie Consult (DEC Consult,
permit number EMC2646), a Dutch independent animal experimentation
ethics review board. Animals were housed in groups, received standard
primate feed and fresh fruit on a daily basis and had access to water ad
libitum. In addition, their cages contained several sources of environmental
enrichment, for example hiding places, hanging ropes, tires, and other
toys. During the vaccination and challenge periods (0–24 DPV and 0–24
DPC) animals were housed in HEPA-ﬁltered, negatively pressurized ABSL-3
isolator cages, both to ensure biological containment of the genetically
modiﬁed viruses and to reduce stress during the repeated sample
collection by using the squeeze mechanism for sedating the animals.
Animal welfare was observed on a daily basis, and all animal handling was
performed under light anesthesia using ketamine and medetomidine (50/
50 v/v, 0.2 ml/kg body weight, IM injection). After handling, atipamezole
was administered to antagonize the effect of medetomidine (0.05ml/kg
body weight, IM injection). The manuscript was prepared in accordance
with the “Animal Research: Reporting of In Vivo Experiments” (ARRIVE)
guidelines.
Animal study design
Forty-eight male cynomolgus macaques (Macaca fascicularis) were immu-
nized with 104 TCID50 of rMV
EZEGFP(3) administered via four different
routes of administration: IM injection (n = 12), IN instillation (n = 12),
IT inoculation (n = 12) or AI (n = 12) (Fig. 1a).
The standard route of MV vaccination is SC injection. However, the skin
of macaques is more loosely connected to the subcutus than the skin of
humans, therefore, we chose to use IM rather than SC injection to avoid
redistribution of the vaccine over a large surface area. Several studies have
demonstrated that both routes are safe and effective in humans.53, 54 IM
injection was performed in 0.5 ml into the rectus femoris. IN instillation was
included as a route of administration to assess tropism and immunogeni-
city if the complete vaccine dose was delivered to the URT only. IN
instillation (0.5 ml) was performed by using a Gilson P200 pipette, dividing
the volume over both nostrils. Immediately after instillation, the nostrils
were gently squeezed from the outside to distribute the vaccine virus over
the surfaces of the nasal cavity. IT instillation was included as a route of
administration to assess tropism and immunogenicity if the complete
vaccine dose was delivered to the LRT. Immediately before IT instillation
the vaccine virus was diluted 1:10 in phosphate-buffered saline (PBS,
Gibco), and 5ml was inoculated IT through a ﬂexible catheter inserted into
the trachea just below the larynx. AI was performed as described.25 Brieﬂy,
Fig. 5 Protection. Immunization of non-human primates with rMVEZEGFP(3) via four different routes of administration induced varying levels
of protection to IT challenge with wild-type MV strain Bilthoven 14 MPV. In panels a–d symbols represent individual animals: a, b show MV-
speciﬁc serum antibody levels before challenge as measured by ELISA or FRNT, respectively (in panel b the dotted lines show the upper limit of
detection of the two assays that were performed); c, d show frequencies of wild-type MV-infected BAL cells and PBMC after challenge
infection, respectively. Panels e, f show MV-speciﬁc serum antibody levels after challenge, demonstrating accelerated secondary immune
responses in all vaccinated animals as compared to slow primary responses in the challenge control animals (means± standard error per
group). Symbol colors and shapes for vaccinated animals are identical to those in Figs. 1–4, black symbols represent challenge controls
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vaccine virus was nebulized using a vibrating mesh nebulizer (Aeroneb
Pro, Aerogen Ireland Ltd., mass median aerodynamic diameter 3.5 µm),
connected to a 22mm T-piece and using a silicone pediatric resuscitation
mask (Laerdal 0/0) as interface with the macaque. Bench studies
performed using macaque breathing parameters demonstrated that
approximately 25% of a nebulized dose was inhaled by the animal,
whereas the remainder of the dose was lost as condensate in the nebulizer
or T-piece or was exhaled. Therefore, 0.5 ml of a 4× concentrated vaccine
virus stock was nebulized to deliver the same vaccine dose as in the other
three groups. It should be noted that there is no control over the fate of
the inhaled vaccine virus after inhalation: part may be lost when it gets
swallowed, whereas the remainder will be deposited in the URT or the LRT.
Six animals of each of the four vaccination groups were used to study
viral tropism. These were euthanized 3 (n = 2), 5 (n = 2), or 7 (n = 2) DPV.
The other six animals/group were followed up for 14 months to study
immunogenicity, and were subsequently challenged with wild-type MV. An
additional four unvaccinated animals were included as challenge controls.
Due to the limitations of housing facilities and laboratory capacity, the
experiment was performed in two parallel sessions with separate
vaccination and challenge days but sticking to identical time intervals.
The study design is summarized in Fig. 1, animal numbers, characteristics,
vaccination routes, and sample collection time points are listed in
Supplementary Table 1.
Sample size estimation, randomization, and blinding
In the replication and tropism arm of the study, the main outcome
parameters were qualitative assessment and characterization of EGFP-
positive cells at early time points after vaccination. We selected three time
points of euthanasia (3, 5 and, 7 DPV) based on the expected peak of virus
replication as determined in previous measles vaccination studies in the
macaque model, and chose to include two animals at each time point
(leading to a total group size of 6). In the immunogenicity and protection
arm of the study, the required group size was based on a power calculation
using MV-speciﬁc serum antibody responses as main outcome parameter.
Based on variation in antibody responses in previous non-human primate
vaccination studies, we estimated that a group size of six animals would
result in adequate statistical power.
Upon arrival from the supplier, animals were randomly assigned to
groups of three animals. These groups were maintained as much as
possible for the complete duration of the study, and only modiﬁed in the
beginning if animals were not socially compatible. Stable groups of non-
human primates should not be changed, and, therefore, the same group
composition was used when the animals were moved into DM-III isolators
for their vaccinations. Which isolator was used for each route of
administration was selected randomly (without using a formal randomiza-
tion procedure).
During sample collection, tubes were labeled with the last four digits of
the animal identiﬁcation chip number, and subsequently transported to
the lab. Laboratory technicians were not aware which animal number
corresponded to which of the different treatment groups.
Viruses
Animals were vaccinated with rMVEZEGFP(3). Non-recombinant vaccine
virus, MRC-5 cells and protocols for vaccine production and formulation
were kindly provided by the Serum Institute of India. Generation,
formulation, and characterization of the recombinant vaccine virus was
described previously.24 The formulated vaccine virus had a history of one
passage in Vero-hCD150 cells (rescue) and ﬁve passages in MRC-5 cells,
and was stored at −80 °C. The stock had a titer of 106.6 TCID50/ml, and was
diluted in formulated medium24 to 104 TCID50 per 0.5 ml. Challenge
infections were performed by IT inoculation with wild-type (non-
recombinant) MV strain Bilthoven, as described previously.14, 27
Samples
Small-volume EDTA blood samples were collected in Vacuette tubes
containing K3EDTA as an anticoagulant. Plasma was separated from
the blood by centrifugation, heat inactivated (30min; 56 °C), and stored at
−20 °C. PBMC were isolated from EDTA blood by density gradient
centrifugation and resuspended in complete RPMI 1640 medium (Gibco
Invitrogen, Carlsbad, CA) supplemented with L-glutamine (2 mM), 10% (v/v)
FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml). BAL was
performed in animals of the immunogenicity arm at 3, 6, and 9 DPV and
3, 6, and 9 days DPC by IT infusion of 10ml PBS through a ﬂexible catheter
followed by immediate recovery of the ﬂuid. BAL samples were
centrifuged, and BAL cells were resuspended in culture medium with
supplements as described above. Throat brushes and nasal swabs were
collected in virus transport medium as described elsewhere.19 For the virus
tropism study, animals were euthanized by exsanguination under deep
anesthesia using ketamine and medetomidine. During necropsy, tissue
samples were collected in PBS and directly processed and screened for the
presence of EGFP by UV microscopy. EGFP-positive samples were either
transferred to 4% (w/v) paraformaldehyde in PBS (to preserve EGFP
autoﬂuorescence) for direct imaging, to 10% (v/v) neutral-buffered
formalin for parafﬁn embedding or to the laboratory for preparation of
single-cell suspensions for ﬂow cytometry. Direct imaging was performed
by confocal laser scanning microscopy with a LSM700 system ﬁtted on an
Axio Observer Z1 inverted microscope (Zeiss), and images were generated
using Zen software version 2010B SP1.
Virus detection
Isolation of MV vaccine or wild-type virus was performed on Vero or Vero-
hCD150 cells (kind gift of Dr Y. Yanagi, Fukuoka, Japan),26 respectively. All
cell lines tested negative for mycoplasma spp. contamination. Virus
isolation was performed by infectious-center test as previously described,55
monitoring for cytopathic effect and/or ﬂuorescence 6 days post-isolation.
Results of vaccine virus isolations are shown as positive or negative
(regardless of load), results of wild-type MV isolation are shown as the
number of infected cells per million. Flow cytometry was used to detect
EGFP-positive MV-infected cells in PBMC or single-cell suspensions of
lymphoid tissues. Immunohistochemistry (IHC) was performed as
described previously.24 Brieﬂy, GFP was visualized in IHC and dual-
labeling indirect immunoﬂuorescence with a polyclonal rabbit anti-EGFP
(Invitrogen) or rabbit anti-MV (Novus Biologicals) antibody. Monoclonal
mouse antibodies to the macrophage marker CD68 (Dako; clone KP1) or
the epithelial cell marker Cytokeratin (Abcam; clone Ae1/Ae3) were used to
visualize the respective cell types. In dual-labeling immunoﬂuorescence,
antigen-binding sites were detected with a mixture of anti-mouse Alexa
568 and anti-rabbit Alexa 488 (Invitrogen). Sections were counterstained
with 4’,6-diamidino-2-phenylindole (DAPI) hard-set mounting medium
(Vector). Fluorescently stained slides were examined at ×100, ×200, ×400,
and ×1000 magniﬁcations on a ﬂuorescence imaging microscope (Leica
Microsystems).
Virus-speciﬁc immune responses
MV-speciﬁc antibody levels were measured in serum (virus neutralization)
or EDTA plasma samples (all other serological assays). The ELISA classic
Measles Virus IgG assay (Serion, Würzburg, Germany) was performed
according to the instructions of the manufacturer. The in house MV-
speciﬁc IgG ELISA, MV-N-speciﬁc IgG ELISA, and the MV-F and MV-H
glycoprotein-speciﬁc indirect immunoﬂuorescence assays were performed
as described previously.56 In all cases, bound antibodies were detected by
polyclonal anti-human IgG conjugates that show excellent cross-reactivity
with macaque IgG.
Virus neutralizing antibodies were detected using a ﬂuorescent focus
reduction neutralization assay,57 with some modiﬁcations. Brieﬂy, Vero-
hCD150 cells were seeded in 96-well ﬂat-bottom plates (Greiner) in RPMI-
1640 supplemented with 10% (v/v) fetal bovine serum (FBS) 4 days before
the experiment, and refreshed with RPMI-1640 medium supplemented
with 2% (v/v) FBS (R2F) the day before the experiment. Serial dilutions
(22–29, each dilution tested in triplicate) of heat inactivated serum in R2F
were mixed 1:1 (v/v) with 40 TCID50 of rMV
EZEGFP(3), and incubated for 90
min at 37 °C. Subsequently, the serum/virus mixtures were transferred to
the Vero-hCD150 monolayers and spinoculated for 15min at 1200×g. Cells
were cultured at 37 °C for 2 h, after which fusion inhibitory peptide (FIP: Z-
d-Phe-L-Phe-Gly-OH, Bachem, Heidelberg, Germany) was added to a ﬁnal
concentration of 0.2 mM to prevent cell-to-cell fusion. Two days later,
plates were washed with PBS, ﬁxed with 1% (w/v) paraformaldehyde in
PBS, and single ﬂuorescent cells were counted using an automated
ﬂuorescence imager (ImmunoSpot S6 analyzer, CTL, Bonn, Germany).
Graphpad Prism 5.01 software was used to calculate sigmoidal
dose–response curves, on basis of which a 50% reduction titer (EC50)
was determined. Results were expressed in international units per ml using
the WHO 3rd international reference serum for measles (NIBSC, South
Mimms, United Kingdom).
Puriﬁed MV Edmonston with a concentration of approximately 1 mg/ml
was inactivated by UV-irradiation (30 min, 15W 312 nm), for cellular assays
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and is hereafter referred to as UV-MV. A Vero cell lysate was also UV-
irradiated, and used as mock control antigen (hereafter referred to as UV-
Vero). PBMC were thawed and allowed to recover overnight at 37 °C in
RPMI-1640 supplemented with 10% (v/v) human serum, 1% (v/v) macaque
serum, and 3.5 ng/ml recombinant human IL-7 (ImmunoTools, Friesoythe,
Germany). The following day cells were counted and plated in 96-well
round-bottom plates (Greiner) at a concentration of 3 × 105 cells per well.
Triplicate cultures were stimulated with UV-MV (ﬁnal dilution 1:100), UV-
Vero (ﬁnal dilution 1:100) or medium. Two days later supernatants were
harvested and IFN-γ concentrations were measured using a monkey IFN-γ
ELISA (U-Cytech, Utrecht, Netherlands).
Statistical analyses
Longitudinal data were analyzed in GraphPad Prism version 7.0a, using
grouped analysis: Two-way analysis of variance for repeated measures with
Tukey’s multiple comparisons test. P-values lower than 0.05 were
considered signiﬁcant. This generalized linear model was automatically
parameterized, resulting in 20 degrees of freedom and n-values of 78.
Data availability
All data generated or analyzed during this study are included in this
published article (and its Supplementary Information ﬁles).
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